3Fuster V,Ryden LE,Cannom DS,et al.2011 ACCF/AHA/HRS focused up- dates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J].Circulation,2011,123:e269-e367.
4January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American Col- lege of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society[J].Circulation,2014,130;2071-2104.
5Falk RH.Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation[J].Ann Intern Med,1989,111:107-111.
6Kodama I,Kamiya K,Toyama J.Cellular electropharmacology of amiodarone [J],Cardiovasc Res,1997,35:13-29.
7Rizza C,Valderrabano M,Singh BN.Recurrent torsades de pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease[J].J Cardiovasc Pharmacol Ther,1999,4:129-134.
8Tse HF,Lam YM,Lau CP,et al.Comparison of digoxin versus low-dose amiod- arone for ventricular rate control in patients with chronic atrial fibrillation[J].Clin Kxp Pharmacol Physiol,2001,28:446-450.
9Baroletti S,Catella J,Ehle M,et al.Dronedarone:a review ol characteristics and clinical data[J].Crit Pathw Cardiol,2010,9:94-101.
10Davy JM,Herold M,Hoglund C,et al.Dronedarone for the control of ventricu- lar rate in permanent atrial fibrillation:the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation(ERATO)study[J].Am Heart J,2008,156:527,e521-529.
